Abstract
Thirteen patients with recurrent or advanced endometrial carcinoma were treated with a combination of doxorubicin (40 mg/m 2 IV) and cyclophosphamide (600 mg/m 2 IV). All patients had been refractory to prior radiotherapy nd hormone therapy. None of the patients had received prior chemotherapy. Six of the 13 patients (46%) achieved an objective response: 1 complete response (8%) and 5 partial responses (38%). Median overall survival was 10 months (range 3-20 months). Doxorubicin and cyclophosphamide is an active combination in patients with advanced endometrial cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 181-183 |
| Number of pages | 3 |
| Journal | European Journal of Gynaecological Oncology |
| Volume | 11 |
| Issue number | 3 |
| Publication status | Published - 1990 |
Fingerprint
ASJC Scopus subject areas
- Obstetrics and Gynaecology
- Oncology
Cite this
Treatment of advanced or recurrent adenocarcinoma of the endometrium with doxorubicin and cyclophosphamide. / Campora, E.; Vidali, A.; Mammoliti, S.; Ragni, N.; Conte, P. F.
In: European Journal of Gynaecological Oncology, Vol. 11, No. 3, 1990, p. 181-183.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment of advanced or recurrent adenocarcinoma of the endometrium with doxorubicin and cyclophosphamide
AU - Campora, E.
AU - Vidali, A.
AU - Mammoliti, S.
AU - Ragni, N.
AU - Conte, P. F.
PY - 1990
Y1 - 1990
N2 - Thirteen patients with recurrent or advanced endometrial carcinoma were treated with a combination of doxorubicin (40 mg/m 2 IV) and cyclophosphamide (600 mg/m 2 IV). All patients had been refractory to prior radiotherapy nd hormone therapy. None of the patients had received prior chemotherapy. Six of the 13 patients (46%) achieved an objective response: 1 complete response (8%) and 5 partial responses (38%). Median overall survival was 10 months (range 3-20 months). Doxorubicin and cyclophosphamide is an active combination in patients with advanced endometrial cancer.
AB - Thirteen patients with recurrent or advanced endometrial carcinoma were treated with a combination of doxorubicin (40 mg/m 2 IV) and cyclophosphamide (600 mg/m 2 IV). All patients had been refractory to prior radiotherapy nd hormone therapy. None of the patients had received prior chemotherapy. Six of the 13 patients (46%) achieved an objective response: 1 complete response (8%) and 5 partial responses (38%). Median overall survival was 10 months (range 3-20 months). Doxorubicin and cyclophosphamide is an active combination in patients with advanced endometrial cancer.
UR - http://www.scopus.com/inward/record.url?scp=0025073788&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025073788&partnerID=8YFLogxK
M3 - Article
VL - 11
SP - 181
EP - 183
JO - European Journal of Gynaecological Oncology
JF - European Journal of Gynaecological Oncology
SN - 0392-2936
IS - 3
ER -